IRIS
ARPINO, GRAZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.359
NA - Nord America 5.678
EU - Europa 4.280
SA - Sud America 795
Continente sconosciuto - Info sul continente non disponibili 308
AF - Africa 145
OC - Oceania 8
Totale 17.573
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.421
SG - Singapore 2.728
RU - Federazione Russa 1.751
CN - Cina 1.310
IT - Italia 1.235
VN - Vietnam 1.111
BR - Brasile 623
HK - Hong Kong 494
DE - Germania 273
FR - Francia 234
NL - Olanda 177
CA - Canada 136
IN - India 136
FI - Finlandia 127
GB - Regno Unito 126
BD - Bangladesh 112
JP - Giappone 103
IE - Irlanda 101
KR - Corea 80
AR - Argentina 63
UA - Ucraina 55
MX - Messico 50
ZA - Sudafrica 40
CI - Costa d'Avorio 35
EC - Ecuador 35
PK - Pakistan 35
IQ - Iraq 33
ES - Italia 30
AT - Austria 28
ID - Indonesia 28
PL - Polonia 27
PH - Filippine 26
TH - Thailandia 24
SE - Svezia 23
VE - Venezuela 23
UZ - Uzbekistan 17
JM - Giamaica 16
TR - Turchia 16
CO - Colombia 15
LT - Lituania 14
TW - Taiwan 13
CL - Cile 12
MY - Malesia 12
BE - Belgio 11
MA - Marocco 11
EG - Egitto 10
AE - Emirati Arabi Uniti 9
CZ - Repubblica Ceca 9
ET - Etiopia 9
TN - Tunisia 9
HN - Honduras 8
JO - Giordania 8
LV - Lettonia 8
NP - Nepal 8
PY - Paraguay 8
RO - Romania 8
AU - Australia 7
DO - Repubblica Dominicana 7
IR - Iran 7
KE - Kenya 7
UY - Uruguay 7
CR - Costa Rica 6
GT - Guatemala 6
PE - Perù 6
PS - Palestinian Territory 6
AL - Albania 5
LB - Libano 5
BH - Bahrain 4
BZ - Belize 4
DZ - Algeria 4
IL - Israele 4
MN - Mongolia 4
NG - Nigeria 4
NI - Nicaragua 4
RS - Serbia 4
SA - Arabia Saudita 4
TT - Trinidad e Tobago 4
BF - Burkina Faso 3
BO - Bolivia 3
BY - Bielorussia 3
CH - Svizzera 3
DK - Danimarca 3
EU - Europa 3
HR - Croazia 3
MD - Moldavia 3
PR - Porto Rico 3
PT - Portogallo 3
SN - Senegal 3
SY - Repubblica araba siriana 3
XK - ???statistics.table.value.countryCode.XK??? 3
AF - Afghanistan, Repubblica islamica di 2
AM - Armenia 2
AZ - Azerbaigian 2
BS - Bahamas 2
GE - Georgia 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MK - Macedonia 2
MQ - Martinica 2
MT - Malta 2
Totale 17.232
Salva come PNG Salva come JPEG
Città #
Singapore 1.343
San Jose 970
Hong Kong 477
Chandler 476
Moscow 454
Ashburn 415
Beijing 360
Hefei 340
Ho Chi Minh City 288
Hanoi 264
Santa Clara 234
Naples 208
Council Bluffs 176
The Dalles 154
Los Angeles 141
Amsterdam 138
Napoli 138
Dallas 131
Lauterbourg 130
Millbury 117
Tokyo 94
Munich 93
Princeton 87
Buffalo 82
New York 76
Boston 75
Milan 72
Nanjing 71
São Paulo 62
Seoul 58
Redondo Beach 56
Haiphong 53
Chicago 46
Jacksonville 45
Kochi 43
Rome 43
Des Moines 41
Da Nang 38
Montreal 37
Wilmington 36
Orem 35
Seattle 34
Phoenix 33
Dong Ket 32
Frankfurt am Main 32
Turku 32
Houston 31
Ottawa 31
Pune 28
Toronto 28
London 26
Brooklyn 25
Nanchang 25
Mexico City 24
Nuremberg 24
Warsaw 23
Rio de Janeiro 22
Denver 21
Lawrence 21
Atlanta 20
Hebei 20
Palermo 20
Tianjin 20
Bologna 19
Hải Dương 18
Poplar 18
Stockholm 18
Johannesburg 17
Ninh Bình 17
Helsinki 16
Belo Horizonte 15
Guayaquil 15
Tashkent 15
Dublin 14
Porto Alegre 14
Vienna 14
Baghdad 13
Redwood City 13
Washington 13
Biên Hòa 12
Brasília 12
Can Tho 12
Dearborn 12
Kingston 12
Lappeenranta 12
Shenyang 12
Bangkok 11
Changsha 11
Curitiba 11
Jiaxing 11
Pomigliano d'Arco 11
San Francisco 11
Boardman 10
Charlotte 10
Falkenstein 10
Manchester 10
Salvador 10
Addis Ababa 9
Miami 9
Shanghai 9
Totale 9.245
Salva come PNG Salva come JPEG
Nome #
null 223
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 207
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 196
Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine 187
It is no longer the time to disregard thyroid metastases from breast cancer: A case report and review of the literature 187
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 185
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 184
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients 182
2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility 182
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 178
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations 165
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 165
Prevalence of Sarcopenia in Women with Breast Cancer 164
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 162
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 160
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 159
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 158
Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction 158
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 157
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 157
Tumor characteristics and prognosis in familial breast cancer 154
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 154
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 154
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 150
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 149
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 149
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 148
Long-term survival and BRCA status in male breast cancer: A retrospective single-center analysis 147
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 147
Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: A retrospective study 146
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 145
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 144
Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions 143
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 143
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 141
Predictive value of apoptosis, proliferation, and HER-2 for anthracycline chemotherapy in patients with locally advanced breast cancer 141
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 141
Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract: A case report 140
The importance of using strain derived criteria for detection of subclinical cardiotoxicity in breast cancer patients undergoing anthracycline and trastuzumab 139
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 138
The continuing role of breast fine-needle aspiration biopsy after the introduction of the IAC Yokohama System For Reporting Breast Fine Needle Aspiration Biopsy Cytopathology 138
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type 137
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 137
Core curriculum. Oncologia clinica 137
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study 137
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 136
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 135
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 134
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 133
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET) 130
Breast cancer prognosis in BRCA1/2 mutation carriers: A case control study. 130
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 130
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives 130
Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study 129
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 129
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 128
Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition. 128
GMO-Gestione Malattie Oncologiche in Regione Campania. 127
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer 124
Core curriculum. Oncologia clinica 123
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. 122
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 122
Imaging tests in staging and surveillance of early breast cancer in Italy. changes in routine clinical practice and costs implications 121
Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study 119
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 119
A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases. 119
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. 117
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom? 117
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 116
Cardio-Oncology Challenges in Elderly Patients 114
miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer 112
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome 111
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. 111
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies 111
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. 110
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. 109
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer 108
Triple-negative breast cancers: Biomarkers and outcomes 106
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study 104
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): an Italian Delphi consensus report 102
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 101
Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. 101
Idoxifene vs. Tamoxifen: A Randomized Comparison in Postmenopausal Patients with Metastatic Breast Cancer 101
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: A multicenter study 101
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 101
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis 99
Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. 99
Capitolo 4 - Terapia Medica 99
HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study 99
Ribociclib in newly diagnosed hepatitis B infection: A case report 98
Features of aggressive breast cancer 96
Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN). 94
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays? 93
Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting 92
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 91
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 90
Prognostic and predictive factors in breast cancer, an evidence-based medicine approach 90
Health-care costs associated with breast cancer management 90
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance 90
Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts. 90
Totale 13.246
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.021
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.021
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022685 0 0 14 4 5 20 7 26 104 98 151 256
2022/20231.115 120 89 30 108 127 134 18 93 151 154 68 23
2023/2024732 34 113 75 39 27 89 11 71 18 22 134 99
2024/20254.326 247 203 47 75 123 204 389 273 410 514 1.471 370
2025/20268.539 899 780 916 755 1.308 414 856 509 1.012 607 201 282
2026/2027782 226 338 218 0 0 0 0 0 0 0 0 0
Totale 17.573